In the published article, there was an error in Table 3 as published. The cell line type and the signalling pathway and mechanism attributed to the article by Garrido-Armas et al. (2018) was incorrect. The corrected Table 3 appear below.
TABLE 3
| Sl. No: | Compounds | Cell line type | Cell line | Signalling pathway and mechanism | References | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1. Breast | ||||||||||||||||||||||||||||
| i) | Curcumin | Melanocyte | MDA-MB-434S | Inhibition of mitochondrial Na+/Ca2+ exchanger (mNCX) and proteasome, pERK1/2↑, p-JNKs↑, Alix↓ | Yoon et al. 2010 (2012) | |||||||||||||||||||||||
| Epithelial | MDA-MB-231, HS578T | |||||||||||||||||||||||||||
| ii) | Dimethoxy curcumin | Melanocyte | MDA-MB-434S | Proteasomal inhibition and ER stress, pERK1/2↑, p-JNKs ↑, Alix↓ | Yoon et al. (2014a) | |||||||||||||||||||||||
| Epithelial | MDA-MB-231, HS578T, MCF-7 | |||||||||||||||||||||||||||
| iii) | Celastrol | Melanocyte | MDA-MB-434S | Ca2+ overload, proteasomal inhibition via ER stress, pERK1/2↑, p-JNKs ↑, p-p38 | Yoon et al. (2014) | |||||||||||||||||||||||
| Epithelial | MCF-7 | |||||||||||||||||||||||||||
| iv) | 15d-PGJ2 | Epithelial | MDA-MB-231 | Disruption of sulfhydryl homeostasis, ER stress, pERK1/2↑ | Kar et al. (2009) | |||||||||||||||||||||||
| v) | Manumycin A | Epithelial | MDA-MB-231, BT-20 | ER stress, accumulation of ubiquitinated proteins, p21↑, p27 ↑, PTEN ↑ | Singha et al. (2013) | |||||||||||||||||||||||
| Lymphoblast | HCC1937 | |||||||||||||||||||||||||||
| vi) | Withaferin A | Epithelial | MDA-MB-231, MCF-7 | ER stress, ROS production, Alix↓ | Ghosh et al. (2016) | |||||||||||||||||||||||
| vii) | Deoxyelephantopin derivative (DETD) | Epithelial | MDA-MB-231 | Oxidative and ER stress, p-JNK↑ | Shiau et al. (2017) | |||||||||||||||||||||||
| viii) | Chalcomoracin | Epithelial | MDA-MB-231 | ROS production, PINK1 ↑, Alix ↓, p-ERK↑ | Han et al. (2018) | |||||||||||||||||||||||
| ix) | 6-Shogaol | Epithelial | MDA-MB-231 | Proteasomal inhibition, ER stress | Nedungadi, et al. (2018) | |||||||||||||||||||||||
| x) | Plumbagin | Epithelial | MDA-MB-231 | Disruption of sulfhydryl homeostasis and inhibition of proteasome | Binoy et al. (2019) | |||||||||||||||||||||||
| xi) | 2′-hydroxy-retrochalcone | Epithelial | MDA-MB-231 | Proteasomal dysfunction and ER stress | Nedungadi et al. (2021) | |||||||||||||||||||||||
| xii) | Indirubin-3′-monoxime (I3M) | Epithelial | MDA-MB-231 | Proteasomal dysfunction and ER stress-mediated Ca2+ release. | Dilshara et al. (2021) | |||||||||||||||||||||||
| xiii) | Cannabinoids (C6 combination) | Epithelial | MDA-MB-231, MCF-7 | ER stress (GRP78 increase) | Schoeman et al. (2020) | |||||||||||||||||||||||
| xiv) | Gambogic Acid | Epithelial | MDA-MB-453, MDA-MB-468, MDA-MB-435S | Disruption of thiol proteostasis | Seo et al. (2019) | |||||||||||||||||||||||
| Melanocyte | ||||||||||||||||||||||||||||
| xv) | 5,7-dibromo-8-(methoxymethoxy)-2-methylquinoline (HQ-11) | Epithelial | MDA-MB-231, MCF-7 | ER stress, proteasomal inhibition, pERK↑ | Ma et al. (2022) | |||||||||||||||||||||||
| xvi) | Glabridin | Epithelial | MDA-MB-231, MCF-7 | ER stress, poly ubiquitinated protein accumulation, proteasome suppression, ROS production, MMP loss | Cui and Cui (2022) | |||||||||||||||||||||||
| xvii) | Isoxazole derivative of usnic acid | Epithelial | MDA-MB-231, MCF-7 | ER stress, IP3R channel activation | Pyrczak-Felczykowska et al. (2022) | |||||||||||||||||||||||
| xviii) | Derivative of pyrazolo[3,4-h]quinoline scaffold (YRL1091) | Epithelial | MDA-MB-231, MCF-7 | ER stress, accumulation of ubiquitinated proteins, ROS production, ERK↑, JNK↑, Alix↓ | Nguyen et al. (2022) | |||||||||||||||||||||||
| xix) | Ginger extract | Epithelial | MDA-MB-231 | ER stress, mitochondrial dysfunction, AIF translocation and DNA damage | Nedungadi et al. (2021) | |||||||||||||||||||||||
| xx) | Disulfiram oxy-derivatives | Epithelial | MCF-7 | ER stress, mitochondrial damage, 20S proteasome inhibition and actin depolymerization at later stages | Solovieva et al. (2022) | |||||||||||||||||||||||
| 2. Brain | ||||||||||||||||||||||||||||
| i) | Curcumin | Glioblastoma | A172 | via microRNAs, AKT-Insulin, and p53-BCL2 networks, and AKT protein level reduction was confirmed | Garrido-Armas et al. (2018) | |||||||||||||||||||||||
| ii) | Ophiobolin A | Pleomorphicastrocytoid, Neuronal, Fibroblast, Fibroblast) Fibroblast | U373-MG, U251N, U251MG, A172 | ER stress, NAC inhibition, decrease of BKCa channel | Bury et al. (2013) | |||||||||||||||||||||||
| T98G | ||||||||||||||||||||||||||||
| iii) | Oligomeric Procyanidins | Epithelial | U-87 | Extracellular Ca2+ influx, pERK1/2↑, p-p38 ↑ | (Zhang et al., 2010) | |||||||||||||||||||||||
| iv) | Paclitaxel | Epithelial | U-87 | CHX has no effect, MEK, p38 and JNK pathways are not involved | Sun et al. (2010) | |||||||||||||||||||||||
| v) | Yessotoxin | Muscle cells from intracranial tumor | BC3H1 | ER and mitochondrial swelling, p-JNK↑ | Korsnes et al. (2011) | |||||||||||||||||||||||
| vi) | 1-Desulfo Yessotoxin | Muscle cells from intracranial tumor | BC3H1 | ER and mitochondrial swelling, p-p38↑ | Korsnes et al. (2013) | |||||||||||||||||||||||
| vii) | Xanthohumol | Epithelial | SH-SY5Y | ER stress and LC3B upregulation, p38 ↑ | Mi et al. (2017) | |||||||||||||||||||||||
| 3. Blood | ||||||||||||||||||||||||||||
| i) | Honokiol | Lymphoblast | K562 | ROS generation ROS generation, ER stress, LC3 upregulation, mTOR and MAPK activated | Liu et al. (2021), Wang et al. (2013) | |||||||||||||||||||||||
| Promyelocyte | NB4 | |||||||||||||||||||||||||||
| ii) | Xanthohumol | Promyeloblast | HL-60 | ER stress and LC3B upregulation, p38 ↑ | Mi et al. (2017) | |||||||||||||||||||||||
| iii) | Iturin lipopeptide | Lymphoblast | K562 | LC3B and p62 upregulation | Zhao et al. (2019) | |||||||||||||||||||||||
| iv) | Brassinin | Lymphoblast | K562 | ROS production, mitochondrial damage, ER stress, and activation of MAPK | Yang et al. (2023) | |||||||||||||||||||||||
| Lymphoblast-like | KBM5, LAMA84, and KCL22 | |||||||||||||||||||||||||||
| 4. Cervical | ||||||||||||||||||||||||||||
| i) | Celastrol | Epithelial | HeLa | Proteasome inhibition, Mitochondrial Ca2+ overload, pERK1/2↑, p-JNKs ↑, p-p38 ↑ | Wang et al. (2012) | |||||||||||||||||||||||
| ii) | Cyclosporin A | Epithelial | HeLa, SiHa | LC3 upregulation, Cyclophilin B↓, Alix↓ | Ram and Ramakrishna (2014) | |||||||||||||||||||||||
| iii) | 8-p-Hydroxybenzoyl tovarol | Epithelial | HeLa | Bip, CHOP, IRE1α and XBP1 upregulation | Zhang et al. (2015) | |||||||||||||||||||||||
| iv) | Seleno-DL-Cystine | Epithelial | HeLa | Bip and CHOP polyubiquitination upregulation, ROS generation | Wallenberg et al. (2014) | |||||||||||||||||||||||
| v) | Paclitaxel | Epithelial | HeLa | CHX has no effect, MEK, p38 and JNK are not involved | Sun et al. (2010) | |||||||||||||||||||||||
| vi) | Wheat germ Agglutinin | Epithelial | HeLa, SiHa, CaSKi | Autophagy-linked FYVE (Alfy) protein inhibition, ER stress, LC3B upregulation | Tsai et al. (2017) | |||||||||||||||||||||||
| vii) | 2′-hydroxy-retrochalcone | Epithelial | HeLa | Proteasomal dysfunction, ER stress, LC3 upregulation | Nedungadi et al. (2021) | |||||||||||||||||||||||
| 5. Thyroid | ||||||||||||||||||||||||||||
| i) | Tunicamycin | Epithelial | 8505C, CAL62, FRO cell lines | Bip, CHOP, p-PERK and IRE1 upregulation | Kim et al. (2014) | |||||||||||||||||||||||
| 6. Liver | ||||||||||||||||||||||||||||
| i) | Hesperidin | Epithelial | HepG2 | Mitochondrial dysfunction and Ca2+ overload, p-ERK↑ | Yumnam et al., 2016) | |||||||||||||||||||||||
| ii) | Cis-Nerolidol | Epithelial | HepG2/C3 A | ER stress, increased activity of cytochrome P450 enzymes | Biazi et al. (2017) | |||||||||||||||||||||||
| iii) | Gambogic Acid | Epithelial; diffusely spreading cells | SNU-449 | Proteasomal inhibition and ER stress, ROS independent- mitochondrial depolarization | Seo et al. (2019) | |||||||||||||||||||||||
| 7. Colon | ||||||||||||||||||||||||||||
| i) | Curcumin | Epithelial | HCT116 | Proteasome inhibition ROS, Mitochondrial Ca2+ overload, LC3 upregulation, pERK1/2↑, p-JNKs↑, Alix↓ | Lee et al. (2015) | |||||||||||||||||||||||
| ii) | Celastrol | Epithelial | DLD-1, RKO | Proteasome inhibition, Mitochondrial Ca2+ overload, pERK1/2↑, p-JNKs ↑, p-p38 ↑ | Yoon et al. (2014) | |||||||||||||||||||||||
| iii) | 15d-PGJ2 | Epithelial | HCT116 | Disruption of sulfhydryl homeostasis LC3 upregulation, pERK1/2↑ | Kar et al. (2009) | |||||||||||||||||||||||
| iv) | Ginsenoside Rh2 | Epithelial | HCT116, SW480 | p53 activation, activation of death by antioxidants | Li et al. (2011), Wan et al. (2018) | |||||||||||||||||||||||
| v) | Protopanaxadiol | Epithelial | HCT116, SW480 | Death acceleration by inhibiting ROS generation, NF-κB activated | Wang et al. (2013) | |||||||||||||||||||||||
| vi) | ɣ-Tocotrienol | Epithelial | SW620 and HCT-8 | Wnt signals↓ (β-catenin, cyclin D, c-Jun) | Zhang et al. (2011) (2013) | |||||||||||||||||||||||
| δ-Tocotrienol | Epithelial | SW620 | Wnt signals↓ (β-catenin, cyclin D, c-Jun) | |||||||||||||||||||||||||
| vii) | Iturin A-like lipopeptides | Epithelial | Caco-2 | ER stress, ROS generation, Ca2+ ↑ | Zhao et al. (2019) | |||||||||||||||||||||||
| viii) | Loperamide | Epithelial | DLD-1, SW-480, SW-620, HCT116 | ER stress, Ca2+ imbalance and CHOP↑ | Kim et al. (2019) | |||||||||||||||||||||||
| ix) | Purified resin glycoside fraction (Pharbitidis Semen) | Epithelial | HT-29 and HCT-116 | Chloride intracellular channel-1 activation and intracellular Cl−↑, MAPK activation | Zhu et al. (2019) | |||||||||||||||||||||||
| 8. Prostate | ||||||||||||||||||||||||||||
| i) | Curcumin | Epithelial | PC-3M | Proteasome inhibition ROS, Mitochondrial Ca2+ overload, LC3 upregulation, pERK1/2↑, p-JNKs↑, Alix↓ | Lee et al. (2015) | |||||||||||||||||||||||
| ii) | 15d-PGJ2 | Epithelial | DU145 | Disruption of sulfhydryl homeostasis LC3 upregulation, pERK1/2↑ | Kar et al. (2009) | |||||||||||||||||||||||
| iii) | Benzo[a]quinolizidine analogs | Epithelial | PC3 | ER stress and LC3B upregulation | Zheng et al. 2016) | |||||||||||||||||||||||
| iv) | Chalcomoracin | Epithelial | LNCaP, PC-3 | ROS generation, ER stress, PINK1 ↑, Alix ↓, p-ERK↑ | Han et al, 2018) | |||||||||||||||||||||||
| v) | δ-Tocotrienol | Epithelial | CRPC cells—DU145, PC-3 | ER stress, LC3 and p62 upregulation, p-JNK ↑, p-p38 ↑ | Fontana et al. (2020) | |||||||||||||||||||||||
| 9. Ovarian | ||||||||||||||||||||||||||||
| i) | Morusin | Epithelial | A2780, HO-8910, SKOV3 | Ca2+ overload, ROS generation and loss of mitochondrial membrane potential | Xue et al. (2018) | |||||||||||||||||||||||
| ii) | Elaiophylin | Epithelial | SKOV3, OVCAR8, UWB1.289, SW626 | ER stress, SHP2/SOS1/MAPK↑ | Li et al. (2022) | |||||||||||||||||||||||
| 10. Lung | ||||||||||||||||||||||||||||
| (i) | Cyclosporin A | Epithelial | A549 | LC3 upregulation, Cyclophilin B↓, Alix↓ | Ram and Ramakrishna (2014) | |||||||||||||||||||||||
| ii) | Paclitaxel | Epithelial | A549 | CHX has no effect, MEK, p38 and JNK are not involved | Guo et al. (2010) | |||||||||||||||||||||||
| Epithelial | ASTC-a-1 | |||||||||||||||||||||||||||
| iii) | 6-Shogaol | Epithelial | A549 | Proteasome inhibition, ER stress, ROS generation, LC3 upregulation | Nedungadi et al. (2018) | |||||||||||||||||||||||
| iv) | Hinokitiol copper complex | Epithelial | A549 | Proteasome inhibition, ER stress | Chen et al. (2017) | |||||||||||||||||||||||
| v) | Chalcomoracin | Epithelial | H460 | ER stress, MAPK activation | Han et al. (2018) | |||||||||||||||||||||||
| Epithelial | A549 | |||||||||||||||||||||||||||
| Adenocyte | PC-9 | |||||||||||||||||||||||||||
| vi) | Paris Saponin II (PSII) | Epithelial | NCI-H460 | ER stress, JNK pathway activation | Man et al. (2020) | |||||||||||||||||||||||
| Epithelial | NCI-H520 | |||||||||||||||||||||||||||
| vii) | Prenylated bibenzyls (Radula constricta) | Epithelial | A549, NCI-H1299 | ROS elevation and loss in mitochondrial membrane potential | Zhang et al. (2019) | |||||||||||||||||||||||
| viii) | Gambogic Acid | Epithelial | NCI-H460 | Proteasomal inhibition and ER stress, ROS independent- mitochondrial depolarization | Seo et al. (2019) | |||||||||||||||||||||||
| ix) | Epimedokoreanin B | Epithelial | A549, NCL-H292 | ER stress, autophagosome accumulation, ROS production, loss of MMP, UPR signaling | Zheng et al. (2022) | |||||||||||||||||||||||
| x) | DHW-221 | Epithelial | A549 | ER stress, PI3K/mTOR inhibition, MAPK activation | Liu et al. (2022) | |||||||||||||||||||||||
| xi) | Ginger extract | Epithelial | A549 | ER stress, mitochondrial dysfunction, AIF translocation and DNA damage | Nedungadi et al. (2021) | |||||||||||||||||||||||
| 11. Skin | ||||||||||||||||||||||||||||
| i) | Cyclosporin A | Keratinocyte | HaCaT | LC3 upregulation, Cyclophilin B↓, Alix↓ | (Ram and Ramakrishna (2014) | |||||||||||||||||||||||
| ii) | δ-tocotrienol | Epithelial | A375 | Ca2+ overload and ROS generation, MAPK activation | Raimondi et al. (2021) | |||||||||||||||||||||||
| 12. Bone | ||||||||||||||||||||||||||||
| i) | Cyclosporin A | Epithelial | U2OS, Saos-2 | LC3 upregulation, Cyclophilin B↓, Alix↓ | Ram and Ramakrishna (2014) | |||||||||||||||||||||||
| 13. Kidney and Bladder | ||||||||||||||||||||||||||||
| i) | Jolkinolide B | Epithelial | T24, UM-UC-3, T24/CDDP | ROS-mediated ER stress, MAPK and ERK activation | Sang et al. (2021) | |||||||||||||||||||||||
| 14. Oral | ||||||||||||||||||||||||||||
| i) | Isorhamnetin (3′-Methoxy-3,4′,5,7-tetrahydroxyflavone) | Epithelial | HSC-3, HSC-4, PE/CA-PJ15 | ↑ROS generation, ERK/MAPK | Chen et al. (2021) | |||||||||||||||||||||||
| 15. Pancreas | ||||||||||||||||||||||||||||
| i) | Gambogic Acid | Epithelial | BxPC-3 | Proteasomal inhibition and ER stress, ROS- independent mitochondrial depolarization | Seo et al. (2019) | |||||||||||||||||||||||
| 16. Stomach | ||||||||||||||||||||||||||||
| i) | Gambogic Acid | Epithelial | SNU-668 (gastric cancer) | Proteasomal inhibition and ER stress, ROS independent- mitochondrial depolarization | Seo et al. 2019) | |||||||||||||||||||||||
Paraptosis-inducing compounds against cancer cell lines.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
cancer, paraptosis, programmed cell death, alternative cell death, cancer therapy, apoptosis
Citation
Hanson S, Dharan A, V. JP, Pal S, Nair BG, Kar R and Mishra N (2023) Corrigendum: Paraptosis: a unique cell death mode for targeting cancer. Front. Pharmacol. 14:1274076. doi: 10.3389/fphar.2023.1274076
Received
07 August 2023
Accepted
25 August 2023
Published
08 September 2023
Volume
14 - 2023
Edited and reviewed by
Zhaoshi Bai, The Affiliated Cancer Hospital of Nanjing Medical University, China
Updates
Copyright
© 2023 Hanson, Dharan, V., Pal, Nair, Kar and Mishra.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nandita Mishra, nanditamishra@am.amrita.edu
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.